FLT3 and acute myeloid leukemia: Crenolanib monotherapy has been studied in several early-phase trials in adults with relapsed/refractory FLT3-mutated AML with encouraging activity (93), and combination trials in patients with newly diagnosed FLT3–ITD AML have demonstrated promising results (94).